Skip to Content

AgeX Therapeutics, Inc.

Merger

  • Date:
  • 8/30/2023
  • Company Name:
  • AgeX Therapeutics, Inc.
  • Stock Symbol:
  • AGE
  • Company Name - Buyer:
  • Serina Therapeutics, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 8/29/2023

Case Finder

Locate any case using the tools below.

NEW YORK, August 30, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of AgeX Therapeutics, Inc. (NYSE: AGE) (“AgeX”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Serina Therapeutics, Inc. (“Serina”).

On August 29, 2023, AgeX announced that it had entered into an agreement to be acquired by Serina in a stock deal. Pursuant to the merger agreement, pre-merger AgeX stockholders are expected to own approximately 25% of the newly combined company while pre-merger Serina stockholders are expected to own approximately 75% of the newly combined company. The deal is expected to close by first quarter of 2024.

Bragar Eagel & Squire is concerned that AgeX's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for AgeX's stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in AgeX Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: